Evidence mapPaperPMID 39202486Full record

ReviewMedicina (Kaunas, Lithuania)2024

From Lipid Signatures to Cellular Responses: Unraveling the Complexity of Melanoma and Furthering Its Diagnosis and Treatment.

Elisa Díaz-Grijuela, Agustín Hernández, Claudia Caballero, Roberto Fernandez, Raquel Urtasun, Marina Gulak, Egoitz Astigarraga, Miguel Barajas, Gabriel Barreda-Gómez

Abstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elisa Díaz-GrijuelaBetternostics SL, 31110 Noáin, Spain.ORCID 0009-0000-3615-3090
Agustín HernándezBetternostics SL, 31110 Noáin, Spain.ORCID 0000-0002-7884-8023
Claudia CaballeroBetternostics SL, 31110 Noáin, Spain.
Roberto FernandezIMG Pharma Biotech, Research and Development Division, 48170 Zamudio, Spain.ORCID 0000-0002-3424-9758
Raquel UrtasunBiochemistry Area, Department of Health Science, Universidad Pública de Navarra, 31006 Pamplona, Spain.ORCID 0000-0003-2332-5361
Marina GulakCruz Roja Hospital, 48013 Bilbao, Spain.
Egoitz AstigarragaBetternostics SL, 31110 Noáin, Spain.ORCID 0000-0002-0338-5554
Miguel BarajasBiochemistry Area, Department of Health Science, Universidad Pública de Navarra, 31006 Pamplona, Spain.ORCID 0000-0003-4004-1432
Gabriel Barreda-GómezBetternostics SL, 31110 Noáin, Spain.ORCID 0000-0002-8330-1567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advancements in mass spectrometry have significantly enhanced our understanding of complex lipid profiles, opening new avenues for oncological diagnostics. This review highlights the importance of lipidomics in the comprehension of certain metabolic pathways and its potential for the detection and characterization of various cancers, in particular melanoma. Through detailed case studies, we demonstrate how lipidomic analysis has led to significant breakthroughs in the identification and understanding of cancer types and its potential for detecting unique biomarkers that are instrumental in its diagnosis. Additionally, this review addresses the technical challenges and future perspectives of these methodologies, including their potential expansion and refinement for clinical applications. The discussion underscores the critical role of lipidomic profiling in advancing cancer diagnostics, proposing a new paradigm in how we approach this devastating disease, with particular emphasis on its application in comparative oncology.

Indexed as

LipidomicsMelanomaBiomarkers, TumorHumansLipid MetabolismLipidsMass SpectrometrySkin NeoplasmsBiomarkers, TumorLipidscomparative oncologylipidomicsliquid biopsymass spectrometrymelanoma

Identifiers

PMID39202486
PMCPMC11356604

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.